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Twenty-Five Years of Progress in the Medical Treatment of Pediatric
and Congenital Heart Disease
DAN G. McNAMARA, MD, FACC
Houston, Texas
In the past 25 years there has been a many-fold increase
in the prospect that with early recognition and modern
treatment the newborn with critical congenital heart dis-
ease will reach adult life in a healthy condition, prepared
to earn a living and to function as a spouse and as a
parent.
Advancements in the medical treatment of congenital
heart disease may create less public acclaim than may
surgical treatment but many purely medical develop-
ments provide the basis for achieving ultimate surgical
success and, by judicious use of some forms of medical
treatment, operation can be avoided altogether.
The eight major contributions to patient care that are
discussed in this review and the 35 that are simply listed
are merely examples of the many developments that have
The 25 year period from January 1958 to January 1983 has
seen many improvements in pediatric cardiology for the
benefit of the infant, child or adolescent who has cardio-
vascular disease and the potential for developing it. Some
advancements have been developed by pediatric cardiolo-
gists; others have been developed by basic scientists or adult
cardiologists and then adapted to the needs of the pediatric
patient. Many important developments were preceded by
years of basic research in order to produce clinically useful
methods of treatment. In other instances investigators promptly
applied new techniques and concepts to meet an urgent
clinical need, conducting little or no preceding fundamental
research.
This review will include only a few of the important
developments since 1958 and it is clearly weighted toward
developments with which I am most familiar. Important
contributions that are not listed have been omitted only to
conserve space. This limited review may prompt others to
prepare an all-inclusive syllabus of historical advances in
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occurred in the past 25 years. These include: 1) the
organization of pediatric cardiology and the contribution
of volunteer health organizations, 2) continuing medical
education aimed at promoting early diagnosis of con-
genital heart disease and prompt referral to a cardiac
center, 3) advances in the technology of cardiac cathe-
terization, 4) Rashkind's balloon atrial septostomy and
other catheter manipulative procedures, 5) pharmaco-
logic manipulation of the ductus, 6) beta-adrenergic
blockade for control of a variety of problems, including
paroxysmal hypoxemic attacks, certain arrhythmias and
relief of symptoms in hypertrophic cardiomyopathy, 7)
echocardiography, and 8) advances in arrhythmias, elec-
trophysiologic studies and use of pacemakers.
pediatric cardiology in which appropriate attention is given
to all investigators and their research products.
The rationale for a 25 year review of developments that
have contributed to patient care is to encourage a new gen-
eration of physicians to see what can be accomplished through
research in such a comparatively short period of time, and
to strive to improve on and surpass these achievements in
answering the unmet needs of patients with pediatric and
congenital heart disease,
Developments in the Organization
of the Discipline of Pediatric Cardiology
Certification Board
In January 1958, approximately 30 pediatricians in the United
States were devoting all or most of their time to heart disease
in children. Probably the greatest boon to the improved
diagnosis and treatment of the infant and child with heart
disease at that time was the establishment of the subspecialty
of pediatric cardiology. Adams (I) described the process as
follows:
"In August 1954 the Committee on Rheumatic Fever and Con-
genital Cardiac Disease of the American Academy of Pediatrics
recommended the creation of a Section on Cardiology within the
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Academy and the establi shment of a cert ification board in pediatr ic
card iology. The Section on Cardiology. however . did not become
formally organized until 1957. the Sub-Board of Pediatric Car-
diology until 196 1. Hugh McCull och and James W. DuShane were
primarily instrumental in formin g the Section on Cardiolo gy. The
first members of the Sub- Board of Pediatric Cardiology were James
W. DuShane , Forrest H. Adams. Edward C. Lambert. Alexander
S. Nadas , Saul J. Robin son and Helen B. Taussig. As with other
specialty boards in medicine. the purposes of the Sub-Board of
Ped iatr ic Cardiology were two-fold : to set minimum standards for
training centers and to certify those physicians possessing the
professional qual ificat ions necessary to practice pediatric
cardio logy . ' :
Growth of the Sub-Board
In 1967 the Board was awarded a contract with the National
Heart and Lung Institute to study the examination procedure
and the activities of Board-certified pediatric cardiologists .
In this study the professional activity of the 207 Board-
cert ified pediatri c cardiologists was sought. Among the 192
who responded . 73% were engaged full-time in pediatri c
cardiology with a medical school, another 20% were based
full-time in a hospital but had no medical school affiliat ion,
and only 12 (7%) of the 192 were engaged in the private
pract ice of pediatric cardiology in an independent office. It
was clear that the field of pediatri c cardiology was not con-
ducive to independent private practice and required full-
time hospital and academic support for success .
Although the diplomates of the Sub-Board of Pediatric
Card iology were mostly academicians , the study uncovered
the surprising fact that the average time spent in research
for the entire group was only 7%: 5% for jun ior full-t ime
faculty and 20% for senior full-time faculty. Patient care
had been changing so rapidly and was so time consuming
that full-time junior and senior academicians were occupied
with patient care an average of 62% of their time. Recog-
nizing the small amount of time devot ed to research, trainin g
program directors began to increase the amount of time
devoted to instruction in investigative techniques and to
allow junior faculty more opportunity for investigative studies.
Contributions to the Growth of Pediatric Cardiology
by Professional Societies
The Cardiology Section of the American Academy of
Pediatrics. Thi s Section was organized in 1957 to provide
a forum for presentation of scientific papers and the ex-
change of ideas among pediatric cardiologists. In addition,
the Section has been continuously concerned with the es-
tablishment of standards of care for cardia c patients (2) .
Council on Cardiovascular Disease of the Young of
the American Heart Association. The American Heart
Association ' s Council on Cardiovascular Disease of the
Young , formerly known as the Council on Rheumatic Fever
and Congenital Heart Disease, has, since its inception. ad-
dressed topics important to treatment of pediatric patient s
with heart disease. including the establishment of standards
for care (3 .4) . Thi s Committee prepares and continually
updates statements for physicians , for example, on prophy-
laxis aga inst infective endocarditis. Council memb ers met
with major life insuranc e comp anies and assisted in the
deve lopment of reasonable criteria for insurability of pa-
tients with congenital heart disease, both preoperative and
postoperati ve (5). Until then . life insurance companies sel-
dom covered the pat ient with any form of congen ital heart
disease .
The Committee on Pediatric Cardiology of the Amer-
ican College of Cardiology. This Committee is now con-
cerned with continuing medical education programs in pe-
diatric and congenital heart disease . Undoubtedly. these
education programs have an influence on patient care
throughout the United State s.
Today there are not enou gh young , recently trained pe-
diatric cardiologists with both strong clinic al skills and a
resea rch background to fill the academic positions that are
avai lable. a problem that will increase during the next 10
years because of attr ition by age . The Committee is studyi ng
these manpower needs for pediatric cardiology in this coun-
try (personal communication: Standing Committee on Pe-
diatric Cardiolog y of the American College of Cardiology:
Graham TP [chairman] , Engle MA , Gutgesell HP, Manning
lA . Nadas AS , Rosenthal A, 1982).
Contributions to Patient Care Through Programs
Supported by the Federal Government
The Inter-Society Commission for Heart Disease
Resources. This Commission was established in 1969 to
set optim al standards for patient care: the report for pedi atr ic
cardiology was published along with the reports for other
disciplines in cardiovascular disease in 1971. The pap er
" Prevention, Acute Care and Long Term Care for Con-
genit al Heart Disease and for Pediatr ic Cardiology" (6) has
set standards adopted by many institutions throu ghout the
country .
The Crippled Children's Services. This agency, de-
veloped in the 1960s. was designed to support the diagnosis
and definitive surgical treatment of infants and children with
congenital heart disease . Its service has provided the means
by which many cardiac programs for children have been
able to function . In some states the Crippled Children 's
Services Advisory Committee is charge d with quality con-
trol by periodic review of the conduct of approv ed programs
of the Crippled Children 's Services .
Training programs. The National Heart, Lung, and
Blood Institute supported clin ical cardio logy train ing for
approxi mately 20 years at a time when the diagnosis and
treatment of each patient with congenital heart diseas e was
virtually a research effort . Many of the current pediatric
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cardiologists in cardiac centers were trained under this pro-
gram. In the past 10 years the Institute's training support
has been confined to research training, thus potentiating our
expectation for further improvement in treatment of heart
disease in the pediatric patient.
Grants-in-aid. The research grants of the National Heart,
Lung, and Blood Institute have provided the means for most
of the developments discussed or listed in this review. Future
improvements in patient care of infants and children with
heart disease will rely on a continuation of this support.
Early Diagnosis and Referral
Changes in Attitude Concerning the Infant With
Congenital Heart Disease
In 1958 cardiac centers were just beginning to take a close
look at the problem of the infant with a morbid form of
congenital heart disease. Before that time many centers put
higher priority on the patient beyond 2 years of age, simply
because the diagnosis and treatment of the older child was
associated with a more favorable outcome. In several reports
in the late 1950s operations for congenital heart defects in
infants who were expected to die proved to be successful,
with early surgical survival in about 70% of them (7). Ochs-
ner et al. (7) pointed out that despite a concerted effort to
treat critically ill infants, during a 6 year period (1954 to
1960) 300 operations were performed on infants under I
year of age for critical congenital heart disease (with a 74%
survival rate), but 1I5 infants with congenital heart disease
under our care died withoutan attempt at surgical treatment,
although half of them had defects amenable to surgery. This
study prompted a more aggressive approach to definitive
diagnosis and treatment in our hospital and probably in
others around the country.
Late Diagnosis of Congenital Cardiac
Defects: Reasons for the Problem and Steps to
Correct It
At this time it became clear that the diagnosis of heart
disease was being made rather late in the course of an
infant's illness (8). This late diagnosis resulted sometimes
because the heart murmur was late in appearing and in other
cases because the symptoms of heart failure in the infant
were nonspecific; these symptoms often suggested disease
of some system other than the cardiovascular, especially
when no heart murmur could be heard (9). Tachypnea in
the infant, despite the absence of other traditional signs of
heart disease, was emphasized as a manifestation of pul-
monary edema and elevated left atrial and pulmonary venous
pressures. Between the years 1969 and 1981, during which
the reasons for late diagnosis and referral were made known
to primary care physicians and nurses responsible for care
of the newborn, the percent of infants referred among the
total number of new patients per year rose from 24 to 46%
and the percent of patients referred on the first day of life
increased from 3 to 13% (10).
Contributions of the New England Regional Infant
Cardiac Program: A Model of Patient Care for
the Nation
This program provided further stimulus for early referral
and served as the standard for the entire country for ideal
management of the infant with critical congenital heart dis-
ease (11). The program was established in 1968 and by
1974, case finding increased by 20% and the number of
deaths in patients not reaching the hospital decreased by
50%. In 1968, 20% of the patients had been referred to the
New England hospitals by less than 2 days of age; by 1977,
34% of the patients referred had reached the hospital by this
age. The New England program did result in a decrease in
the number of hospitals offering infant cardiac services. The
data clearly pointed out what many had suspected. Results
in hospitals with pediatric cardiac services that managed
only a small number of patients per year were inferior to
results in hospitals treating a large number of patients per
year. Patient care was best served by reducing the number
of cardiac centers with a small case load.
Another contribution of the New England Regional Infant
Cardiac Program was that the investigators tabulated the
number of extracardiac anomalies in a large number of pa-
tients (2,251) and found that only 11% of all patients had
a severe uncorrectable extracardiac defect, that is, one that
interfered with the life or well-being of the patient (for
example, Down's syndrome). Another 8% of patients with
a cardiac defect had a severe, but correctable, noncardiac
defect and in yet another 8% the extracardiac defect was
mild and required no treatment. In anomalies such as trans-
position of the great arteries, severe noncardiac anomalies
were extremely rare (0.4%), whereas in anomalies such as
endocardial cushion defect, 45% of the patients had severe
extracardiac anomalies (especially Down's syndrome). If
babies with Down's syndrome are excluded, the patients
with endocardial cushion defect had a 19% incidence rate
of severe extracardiac anomalies.
Some physicians had assumed that patients with con-
genital heart disease had such a large incidence of extra-
cardiac anomalies that major efforts to correct the cardiac
defect might not always be rewarding. Thus, the knowledge
that the number of uncorrectable extracardiac anomalies is
much lower than many physicians thought has been a con-
tribution to the enthusiasm with which pediatricians are
likely to refer and treat these patients and to the willingness
of the state Crippled Children' s Services to continue to
support them.




By Janua ry 1958 , cardiac catheterization and angiographic
techniques had been so well developed during the preceding
10 years that few cardiologists at the time would have ex-
pected much change. Howe ver, the developments in the 25
years after 1958 have been so extensive as to revolutionize
the capabiliti es of the catheterization laborato ry.
Contribution of the Cooperative Study
The cooperative study on cardiac catheterization published
in 1968 by Braunwald and Swan (12) emphasized the high
mortality rate (6 .2%) of cardiac catheterization in infants
less than I month of age and the high complication rate
(15. 3%); subsequently steps were taken in virtually every
center to improve the situation.
The report of the New England Regional Infant Cardiac
Program ( I I) revealed that 2,535 cardiac catheterizations
were performed between 1969 and 1976 and there was no
death within 24 hours of catheterization among infants more
than 4 month s old. Braunwald and Swan (12) reported that
there had been five death s in infants more than 4 months
of age among the I , 161 infant s less than I year of age who
underwent cardi ac catheterization.
Contribution of Technical Advances for Studying
Pediatric Cases
Miniaturization of equipment and supplies. Minia-
turization of equipment and supplies appropriate for use in
the infant brought about a great deal of improvement in the
safety and the information gained from the procedure .
Control of body temperature. Control of body tem-
perature during the procedure added to the safety of cardiac
catheterization . It had not been customary in most centers
to measure body temperature cont inuously or even fre-
quently during cardiac catheterization . Recognizing that in-
creased metabolic activity was harmful to the patient with
congestive heart failure , many clinicians assumed that a low
body temperature might even be somewhat protective and
were inclined to ignore body temperature at less than phys-
iologic range . But the harmful effect of reduced body tem-
perature on cardio vascular function was pointed out in a
study by Silverman et al. (13).
Monitoring of blood gases. Further improvement came
with the frequent monitoring of the patient' s status by blood
gases, pH levels and the metab olic state, all of which could
become quickly altered in the critically ill infant with
congestive heart failure or cyanosis, or both; it was learned
that measurable biochemical changes preceded the clinically
obvious manife stations.
Use of image intensifier. The image intensifier was de-
vised to reduce radiation expo sure to the patient and per-
sonnel . but it also allowed viewing of the fluoroscopic image
with enough light in the room to permit observation of the
clinical appearance of the patient.
Other technical advances. Other advances in the cath-
eteriz ation laboratory include the techn ique for percutaneous
catheter entry (14, 15), the use of disposable catheters. plas-
tic needles for atraumatic arterial cannulation and the de-
velopment of less toxic radiopaque contrast media.
Improved angiographic techniques. The availabilit y
of biplane cineangiography improved diagnostic sensitivity
and accuracy and , by reducing the number of injections of
contrast medium needed and avo iding turning the patient
on the side for a lateral projection , greatly increa sed the
safety of the procedure . Biplane fluoroscopy has added to
the safety of catheter manipulation , by allowing a lateral
view of the course of the catheter, and has further increa sed
the chance of pulmonary artery entry (16).
The angle views of Bargeron et al. (17) first made it
possible to pinpoint the exact location of the ventricular
septal defect as well as the different types of atrial septal
defect. Likewise, these angle positions have allowed an
unobstructed view of the pulmonary artery branches and
have improved ability to detect pulmonary artery branch
stenosis before operation . The use of videotape for im-
mediate replay and review of the angiogram while the patient
is still in the catheterization laboratory has improved di-
agnostic ability in small infants and allows an immediate
decision for treatment while the catheterization is still in
progress.
Umbilical vessel catheterization. Umbilical vessel
catheteriza tion techniques have made it possible to perform
studies of complicated malformations in the first few hours
of life without resorting to percutaneous entry or cut-down
(18, 19).
Transseptalleft heart catheterization. The transseptal
left atrial catheterization was first reported in 1959 (20) , but
the procedure was largely abandoned because of the limi-
tation of equipment and the danger of inadvertent extracar-
diac entry. The use of this technique was revived by Duff
and Mullins (21) and proved feasible in small infants as a
result of improvement of the equipment and the use of the
lateral fluoroscope to more accurately guide the course of
the needle (1 ).
Sedation for cardiac catheterization. In 1958. Smith
et al. (22) reported on their experience with an ataractic
" cocktail" compo sed of meper idine hydrochloride , chlor-
promazine and promethazine for use in infants and children
undergoing cardiac catheterization. This method was adopted
by the majority of catheterization laboratories in this country
and abroad that were concerned with studying infants and
children. Israel et al. (23) studied the effect of this mixture
on the blood gas tension in subjects without card iopulmo-
nary disease and found that in only 3 of the 58 children studied
was there an effect on ventilatory function . The y concluded
that the mixture was safe for use in infants and children
without profound effect on ventilatory function. They did
not . however, study patients with cyanotic heart disea se or
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those with pulmonary edema in whom heavy sedation can
profoundly interfere with gas exchange in the lung and de-
press cardiovascular function. Their study did point out the
advisability of monitoring the arterial blood gases and pH
by the new polarographic and potentiometric techniques for
measuring oxygen and carbon dioxide tension. It may have
been their report on the effect of the catheterization "cock-
tail" that led to the widespread use of monitoring of blood
gas tension and pH during catheterization in order for the
clinician to detect and manage early preclinical changes.
Balloon Atrial Septostomy
William Rashkind's balloon atrial septostomy stands as one
of the most important therapeutic procedures developed in
the past 25 years for the treatment of certain types of con-
genital heart anomalies (24). Also. the concept of balloon
catheter manipulation has had a profound influence on the
entire field of interventional catheterization.
The Rashkind septostomy:
1. Provided a nonsurgical means of creating an atrial septal
defect and thus virtually replaced the Blalock-Hanlon
operation. a procedure that was technically difficult and
carried a mortality rate of 20 to 50%.
2. Increased the safety of cardiac catheterization in the crit-
ically ill neonate with transposition of the great arteries
by providing immediate clinical improvement. a rise in
arterial oxygen saturation when it was severely depressed
and a reduction in left atrial pressure when it was ab-
normally elevated (25).
3. Led to a broadened indication for creation of atrial septal
defect in congenital heart disease, including: (a) pul-
monary valve atresia with intact ventricular septum and
tricuspid atresia with pulmonary stenosis or atresia. so
that, if a later systemic to pulmonary artery anastomosis
must be performed, the large atrial septal defect provides
better toleration of the increased pulmonary venous re-
turn to left atrium (26); (b) total anomaly of pulmonary
venous return, to facilitate blood return to the left heart
chambers (27 ,28).
4. Probably stimulated pediatric cardiologists to use the
Swan-Ganz gas-inflated balloon catheter to flow guide
the catheter tip for difficult entry into certain cardiac
chambers. Because the report of Rashkind and Miller
preceded that of Swan and Ganz (29) by about 4 years.
some have wondered if Rashkind' s balloon catheter stim-
ulated the original concept and development of the Swan-
Ganz flow-directed balloon-tipped catheter. However. I
learned recently that this was not the case. Swan explains
how the idea occurred to him: "One bright fall afternoon
in 1967, while observing the motion of sailboats on Santa
Monica Bay, I wondered if the attachment of a sail to
a cardiac catheter would allow progression to the pul-
monary artery and pulmonary artery wedge posi-
tion.... " (30). Swan discussed his idea with engineers.
It evolved that a balloon would be less cumbersome than
a sail and would avoid the chance of thromboembolic
complications.
Another result of the concept of balloon-tipped cath-
eters was the development by Gruntzig and co-workers
of the method to dilate renal arteries (3 I) and coronary
arteries (32).
The balloon atrial septostomy procedure undoubtedly
stimulated Rashkind himself to think how he could cor-
rect other anomalies by manipulative techniques with
appropriately fashioned catheters. such as the still in-
vestigative umbrella closure of a patent ductus arteriosus
(33).
5. The Rashkind procedure made cardiologists more con-
scious of the dynamics involved in transposition of the
great arteries. total anomaly of pulmonary venous return
and other anomalies in which there is either volume or
pressure load on the right or the left atrium. The pro-
cedure allowed more infants to survive the first few weeks
and months of life and to reach an age and size reasonable
for definitive repair.
The dexterous Rashkind had not appreciated that the pro-
cedure might be less successful in other cardiologists' hands.
Rashkind had taught that rapid withdrawal across the for-
amen ovale of the fully inflated balloon was important. but
he insisted that the procedure is actually very simple: .. All
it requires is a big jerk on the end of the catheter. ..."
Rashkind would quip whenever he was invited to speak on
his method. It was partly Rashkind's humorous and enter-
taining manner of speaking. his enthusiasm for teaching and
his interest in travel that took him to virtually every major
city in most countries of the world to tell about the balloon
catheter and the whole subject of transposition of the great
arteries. Here, for the first time. was a lifesaving procedure
for the patient with transposition which could be carried out
in communities with limited surgical facilities.
However. the technical skill required for successful sep-
tostomy may have discouraged a few cardiologists from
persisting in the method and this limitation of balloon atrial
septostomy may have led some to search for the means to
achieve early definitive repair in anomalies such as trans-
position. Today. in some cardiac centers. these defects can
be surgically corrected in small infants even in the first few
days of life if septostomy is unsuccessful; thus the need for
long-term palliation by creation of a large atrial septal defect
may become less critical. Nonetheless. balloon atrial sep-
tostomy remains useful in a large number of critically ill
infants with congenital heart disease. allowing the patient
to arrive in the operating room in better hemodynamic con-
dition and increasing the chance of long-term survival.




Coceani and Olley (34) demonstrated dilation of the ductus
by infusion of prostaglandin E 1 in fetal lambs. Others con-
firmed the observation in different fetal animals. The drug
was beneficial in opening the ductus and raising the systemic
arterial oxygen saturation in neonatal patients with ductus-
dependent congenital heart defects (35-37). Continuous
administration of prostaglandin E, for hours, days or weeks,
if necessary, may allow either spontaneous improvement
sufficient to stop the treatment or time to prepare for surgical
creation of a systemic to pulmonary artery anastomosis.
Prompted by the finding of Clyman et 11,1. (38) that ductus
relaxation could occur with prostaglandin £1 despite a nor-
mal arterial oxygen tension, Heymann et 11,1. (39) used the
drug successfully in opening the ductus in patients with
interruption of the aortic arch and in those with coarctation
of aorta with closing ductus; Lang et 11,1. (40) reported similar
success.
Prostaglandin E) has been used in the patient with in-
terrupted aortic arch to obtain temporary clinical improve-
ment in the patient's cardiovascular status until a bypass
graft could be placed surgically across the interruption. Sur-
gical success with this anomaly, which is invariably lethal
if untreated in the first few days of life, is now possible in
certain cases because of the improvement obtained with
prostaglandin £1.
In a study involving 56 centers (41), prostaglandin E,
was used in 492 infants with ductus-dependent anomalies.
Prostaglandin £1 provided excellent palliation for the 385
infants with ductus-dependent cyanotic congenital heart dis-
ease. Among the 107 acyanotic patients with either coarc-
tation of the aorta or interrupted aortic arch, dilation of the
ductus produced clinical improvement in 80% of each group
and reduced the pressure gradient from 45 to 9 mm Hg.
Indomethacin
It was not until the mid 1960s that investigators of neonatal
cardiopulmonary problems recognized that a large ductus
arteriosus coexisting with respiratory distress syndrome in
the premature infant could be so silent clinically yet aggra-
vate, if not cause, the pulmonary disease in some 15% of
premature infants weighing less than 1,750 g (42,43). De-
spite small size and poor condition, many such premature
infants who had been unresponsive to digitalis and venti-
latory support recovered after surgical ligation of the
ductus (44-46).
On the basis of knowledge that prostaglandins E) and E2
dilate the naturally constricted ductus in fetal animals and
in neonatal human patients (with a ductus-dependent cardiac
defect), Friedman et 11,1. (47) theorized that administration
of a prostaglandin inhibitor might constrict the ductus. Flower
and Vane (48) had shown that indomethacin is a potent
inhibitor of prostaglandin synthetase. The report of Fried-
man et 11,1. concerned the success with ductus closure after
administration of indomethacin to six consecutive premature
infants for whom surgical ligation of the ductus would or-
dinarily have been performed.
Heymann and Rudolph (49) had inhibited prostaglandin
synthesis in fetal lambs by administration of aspirin and
gave the drug to 3 premature infants with respiratory distress
syndrome with success in I, but confirmed Friedman's re-
sults in ductal constriction with indomethacin in 14 of 15
premature infants.
The studies of Heymann et 11,1. (49,50) demonstrated the
usefulness, and the necessity, of the echocardiogram in sup-
porting the diagnosis of ductus and in following the course
of the infant with critical cardiopulmonary disease during
pharmacologic manipulation of the ductus. Because of the
atypical murmur of ductus in the premature infant, phar-
macologic closure of the ductus often could be confirmed
only by a decrease in the echo-derived ratio of diameter of
left atrium to aortic root. As a result, echocardiographs were
made available to many neonatal intensive care units, aiding
the diagnosis and follow-up of infants with all forms of
cardiopulmonary dysfunction (51,52).
In a large. multicenter. prospective. randomized study
indomethacin has proved to be of value. Nadas, the principal
investigator, at first characteristically cautious about indo-
methacin (53), now has this to say at the end of the study
(which awaits publication): "Indomethacin ought to be used
in small (less than 1,750 g) prematures who have a he-
modynamically significant ductus and who within a short
period of time do not respond to anticongestives." Nadas
and his co-investigators found that in about 75% of cases
the ductus will close with indomethacin. (Nadas AS, per-
sonal communication, 1982.)
Beta-Adrenergic Blockade
Until the mid 1970s the occurrence of a spell of profound
hypoxemia in the patient with tetralogy of Fallot (or other
malformations with ventricular septal defect and severe pul-
monary stenosis) was one of the emergency situations that
called for immediate operation. In many cardiac centers
today, such spells appearing in an infant who is below the
ideal age and size for intracardiac repair can usually be
handled with the use of propranolol. The drug offers the
best medical means currently available to prevent recur-
rences and allows a reasonable delay in definitive surgical
repair.
In 1964, Honey et 11,1. (54) predicted that beta-receptor
blockade would have a place in the treatment of cyanotic
attacks in tetralogy of Fallot. Singh and Gotsman (55) used
the beta-receptor adrenergic blocking agent pronethalol for
the successful treatment of an acute attack.
The study carried out at the Medical University ofSouth
Carolina and reported by Ponce et al. (56) was the first to
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show that propranolol was effective in abolishing spells of
paroxysmal hypoxemia in 17 of their 18 patients, allowing
a delay in operation ranging from 3 to 27 months (55). The
drug was used with 80% success by Garson et al. (57),
allowing a safe delay in operation averaging 13 months.
Propranolol treatment was not associated with low cardiac
output after intracardiac repair. It was once rumored that
propranolol treatment is associated with a high risk of myo-
cardial depression after operation. This widespread notion
was dispelled by the study of Garson et al.
Beta-adrenergic blockade has also found wide use for:
I) relief of symptoms in left ventricular hypertrophic car-
diomyopathy, 2) control of supraventricular tachycardia,
especially in patients who have Wolff-Parkinson-White syn-
drome with short refractory period of the accessory con-
nection, and 3) control of systemic hypertension.
Echocardiography
Diagnostic application. One of the first texts on echo-
cardiography (58) concerned pediatric application of the
method. Echocardiography has become indispensable in the
management of patients with known or suspected congenital
cardiac disease, especially of the seriously ill newborn. In
one of the earliest applications ofM-mode echocardiography
to congenital heart disease, Meyer and Kaplan (59) dem-
onstrated both left and right hypoplastic heart anomalies.
Others demonstrated the utility of echocardiography in the
diagnosis of transposition of the great arteries (60), endo-
cardial cushion defect (61), Ebstein's anomaly (62), tetral-
ogy of Fallot (63) and total anomalous pulmonary venous
connection (64). With the rapid improvement of two-di-
mensional echocardiographic equipment in the mid and late
1970s, it has become possible to make a precise anatomic
assessment of virtually all of the major congenital cardiac
defects (65-67). Perhaps as important as the ability to es-
tablish the diagnosis of congenital heart disease in the neo-
nate is the ability to exclude structural cardiac deformities
as a cause of cyanosis or respiratory distress; today cardiac
catheterization usually can be avoided in the infant with
cyanosis due to lung disease or persistent fetal circulation.
Serial studies. Because it is safe and painless, echo-
cardiography is also valuable in the serial assessment of
children with known cardiac disease. Measurement of sys-
tolic time intervals from pulmonary valve motion provides
an estimate of pulmonary artery pressure with normally
related great arteries (68) and in transposition of the great
arteries (69). Measurement of left ventricular wall thickness
and cavity diameter provides an estimate of left ventricular
pressure in children with aortic valve stenosis (70). Serial
measurement of left ventricular diameter and shortening
fraction may be used to follow changes in ventricular func-
tion in children with myocardial disease (71).
Evaluation of murmurs. In addition to its value in man-
agement of children with serious forms of cardiac disease,
echocardiography has provided an explanation of some car-
diac murmurs in less severe but far more common disorders.
The most notable examples are mitral valve prolapse and
bicuspid aortic valve. Although these lesions are usually of
no hemodynamic significance, noninvasive documentation
provides a rational basis for parental reassurance and for
recommendation of bacterial endocarditis prophylaxis.
Improved Diagnosis and Management of
Cardiac Arrhythmias in Pediatric Patients
Electrophysiologic testing. Our understanding of car-
diac arrhythmias in children began a "growth spurt" in
1969 when Scherlag et al. (72) published their paper on His
bundle recording in human beings. Watson et al. (73) had
published an example of a His bundle recording in 1967,
but the usefulness of the technique was not apparent at that
time. Brodsky et al. (74), Gillette et al. (75) and several
other groups have shown that the technique is feasible in
children.
The usefulness of electrophysiologic testing in children
was amplified by the addition of programmed stimulation
as demonstrated first in the evaluation of arrhythmias after
the Mustard baffle operation for transposition of the great
arteries (76,77). Probably the most important use of elec-
trophysiologic techniques in children has been in the eval-
uation of supraventricular tachycardia (78), particularly that
associated with the preexcitation syndromes (79).
Studies on the mechanisms and potential consequences
of arrhythmias have resulted in a more systematic and suc-
cessful use of antiarrhythmic drugs. Two that have proved
useful in the pediatric patient are verapamil (80) for su-
praventricular reentrant tachyarrhythmias and phenytoin (81)
for ventricular arrhythmias.
Intraoperative applications. Electrophysiologic tech-
niques have been found useful in the cardiovascular oper-
ating room in patients who have tachyarrhythmias resistant
to medical treatment. The Wolff-Parkinson-White syndrome
may be treated with success by operation in more than 90%
of the patients by locating and dividing the accessory con-
nection. Patients without overt Wolff-Parkinson-White syn-
drome may have concealed accessory connections and thus
are candidates for surgery as well (82). Intraoperative map-
ping has also led to the successful surgical treatment of
automatic focus atrial and junctional tachycardias and of
ventricular tachycardia in children (83).
Pacemakers. Technologic advances in pacemakers and
leads have allowed the increased use of pacemakers in chil-
dren (84). The size of both pacemakers and leads has de-
creased so that transvenous techniques are applicable to
children as young as 5 years of age. New pacemakers allow
the restoration of atrioventricular synchrony, thus improving
cardiac performance.




It is difficult to select only eight areas of advancement in
pediatric cardiology that have contributed to the medical
care of the patient since 1958. In preparing for this review
I asked the II members of our faculty in pediatric cardiology
to list the advances of the past 25 years, other than those
that I covered, that they would consider important to the
medical care of the patient. The following list includes only
some of their suggestions, not listed chronologically or in
order of importance:
• Afterload reducing agents
• Neonatal transport
• Neonatal intensive care units
• Better utilization of nursing talent in care of infants with heart
disease
• Microtechniques for blood gases
• Transcutaneous oxygen monitor
• Respirators for ventilatory support
• Twenty-four hour coverage in tertiary care centers for cardiac
catheterization and cardiovascular surgery
• Open radiant warmer for neonatal care
• Doppler blood pressure device
• Nuclear cardiology for quantification of left to right shunt and
for ventilation-perfusion studies
• Telephone electrocardiographic monitor
• Holter 24 hour monitor
• Telemeterized electrocardiographic monitor
• Exercise stress testing
• Antihypertensive treatment
• Potent oral diuretic agents
• Behavioral science in the care of patients with heart disease
• Dopamine and dobutamine for inotropic support
• Recognition of functional differences between developing and
mature myocardium
• Taussig's example of long-term postoperative follow-up
• Improved understanding of "new" problems of the cardiovas-
cular system, including mitral valve prolapse, hypertrophic car-
diomyopathy, Kawasaki's arteritis, cardiomyopathy of infant
of diabetic mother
• Pathogenesis of pulmonary vascular obstructive disease and
prevention by early operation
• Early intervention in living habits to prevent coronary heart
disease
• Calcium channel blockade
• Use of digoxin in place of digitoxin and adjustment of digoxin
dose for premature infants
• Fetal monitoring, including electrocardiogram and echo-
cardiogram
• High fidelity electrocardiographic recording
• Computers for data storage and retrieval
• Monitoring of right and left heart filling pressures
• Intravenous infusion pump for micromedication
• Van Praagh's segmental approach to diagnosis of complex con-
genital heart disease
• Understanding of oxygen toxicity in the neonate and with pro-
longed ventilatory support
• Park knife catheter for creation of atrial septal defect
• Pulmonary vein wedge angiography for distal pulmonary artery
visualization in pulmonary trunk atresia (85).
It is the task of investigators, both current and future, to
explore methods to solve the unmet needs of the pediatric
patient with heart disease or the potential for heart disease.
It is the task of the clinician, who is involved daily with the
diagnosis and treatment of patients with a cardiovascular
problem, to identify these needs, to lay them on the work-
benches of the research laboratories in our academic insti-
tutions and to call for public support of the studies that are
required to respond to these needs.
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